{"id":38553,"date":"2026-05-25T09:50:00","date_gmt":"2026-05-25T13:50:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38553"},"modified":"2026-04-27T22:33:59","modified_gmt":"2026-04-28T02:33:59","slug":"how-pharma-companies-track-ind-nda-dates-to-win-global-patent-extensions","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/how-pharma-companies-track-ind-nda-dates-to-win-global-patent-extensions\/","title":{"rendered":"How Pharma Companies Track IND\/NDA Dates to Win Global Patent Extensions"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition on day one of patent expiry often comes down to a single date buried in a regulatory submission file. That date is the IND effective date or the NDA approval date, and pharmaceutical legal teams, IP strategists, and business development executives treat it with the same reverence that bond traders reserve for Fed announcement days.<\/p>\n\n\n\n

This is the global exclusivity playbook: the system by which companies track, calculate, and leverage key regulatory dates to apply for Patent Term Extensions (PTEs) in the United States and Supplementary Protection Certificates (SPCs) across the European Union, the United Kingdom post-Brexit, Japan, Canada, Australia, and a growing list of additional jurisdictions. Get it right, and you extend the commercial life of a product worth hundreds of millions or billions annually. Get it wrong by even one day, and courts have thrown out entire extension applications, costing companies the full value of that protection.<\/p>\n\n\n\n

The stakes are not abstract. In 2023, the global pharmaceutical market generated approximately $1.48 trillion in revenue [1]. Generic erosion typically strips 80 to 90 percent of brand revenue within the first year of patent expiry [2]. A single successful PTE or SPC application can therefore represent billions of dollars in protected cash flow for a single molecule.<\/p>\n\n\n\n

What follows is a detailed examination of how that system works, where companies make mistakes, how litigation has reshaped the rules, and what the most sophisticated IP departments do differently.<\/p>\n\n\n\n

\n\n\n\n

Part One: The Architecture of Pharmaceutical Patent Extensions<\/strong><\/h2>\n\n\n\n

Why Patents Expire Before Products Launch<\/strong><\/h3>\n\n\n\n

To understand patent extensions, you need to understand the problem they solve. A pharmaceutical patent typically issues somewhere during Phase I or Phase II clinical trials, often eight to twelve years before the drug actually reaches patients. The patent clock runs during all those years of clinical testing, regulatory review, and manufacturing scale-up.<\/p>\n\n\n\n

By the time the FDA approves a New Drug Application (NDA) or a Biologics License Application (BLA), a typical drug has consumed anywhere from eight to fourteen years of its twenty-year patent term in regulatory development alone [3]. Without some mechanism to compensate for this, the effective market exclusivity period for innovative drugs would be, in many cases, shorter than the exclusivity periods granted to generic manufacturers under the Hatch-Waxman Act.<\/p>\n\n\n\n

Congress recognized this problem in 1984 when it passed the Drug Price Competition and Patent Term Restoration Act, better known as Hatch-Waxman. Title II of that legislation created the mechanism for PTEs in the United States. The European Community addressed the same issue eight years later with Council Regulation (EEC) No. 1768\/92, which created the SPC framework. Japan, Canada, Australia, and others followed with their own analogs.<\/p>\n\n\n\n

The basic logic across all of these systems is similar: pharmaceutical companies are entitled to recover some portion of the patent term they lost during mandatory regulatory review. The specific formulas for calculating that recovery differ substantially, and those differences matter enormously in practice.<\/p>\n\n\n\n

The United States PTE Framework: 35 U.S.C. \u00a7 156<\/strong><\/h3>\n\n\n\n

Under U.S. law, a patent covering a drug product, method of use, or manufacturing process is eligible for term extension if the product received its first commercial marketing approval from the FDA [4]. The extension compensates for two distinct periods of regulatory delay.<\/p>\n\n\n\n

The first is the IND testing phase, defined as the period from the filing date of the Investigational New Drug application to the filing date of the NDA or BLA. Only half of this period counts toward the extension calculation.<\/p>\n\n\n\n

The second is the NDA\/BLA review phase, defined as the period from the filing date of the NDA or BLA to the date of approval. The full duration of this period counts.<\/p>\n\n\n\n

The combined extension cannot exceed five years, the total remaining patent term after extension cannot exceed fourteen years from the date of first FDA approval, and no single patent can receive more than one extension.<\/p>\n\n\n\n

The applicant must file the PTE application within sixty days of receiving FDA approval. That sixty-day window is jurisdictionally unforgiving. Courts have consistently refused to allow late filings regardless of circumstances, including the complexity of the calculation or administrative error.<\/p>\n\n\n\n

The USPTO, in consultation with the FDA, makes the final determination. The FDA certifies the regulatory review period, and the USPTO calculates the actual extension period after subtracting any applicant delays during regulatory proceedings.<\/p>\n\n\n\n

Applicant Delays: The Hidden Deduction<\/strong><\/h4>\n\n\n\n

One of the most consequential and underappreciated elements of the PTE calculation is the applicant delay provision. Any period during which the applicant failed to act with due diligence in pursuing FDA approval gets subtracted from the extension. This includes delays in responding to FDA information requests, slow submission of required data, and periods when the application was withdrawn and refiled.<\/p>\n\n\n\n

The due diligence standard is set through an FDA due diligence petition process, and companies that ignored FDA requests during clinical development sometimes discover years later that their PTE is materially shorter than they expected. Tracking these delays contemporaneously, rather than reconstructing them retroactively when filing the PTE application, is one of the practical differentiators between sophisticated and unsophisticated IP departments.<\/p>\n\n\n\n

Which Patent to Extend<\/strong><\/h4>\n\n\n\n

A company often holds multiple patents covering a single approved drug: composition of matter patents, method of use patents, formulation patents, and process patents. Only one can receive the PTE. The choice of which patent to extend involves projecting expiration dates across the entire portfolio, modeling generic entry timing for each patent, and then identifying which extension delivers the longest protection against the most commercially significant risk.<\/p>\n\n\n\n

Companies frequently make this decision suboptimally by defaulting to the composition of matter patent without adequately modeling whether a method of use patent with a later expiration date, extended, would actually provide better protection. DrugPatentWatch provides publicly available patent expiration data for approved drugs, which analysts use to benchmark these calculations against competitive products and reconstruct competitor patent strategies.<\/p>\n\n\n\n

The European SPC Framework<\/strong><\/h3>\n\n\n\n

The SPC system in the European Union operates under Regulation (EC) No. 469\/2009, which consolidated and replaced the original 1992 regulation. Unlike the U.S. system, which is administered at the federal level with a single filing, the SPC is a national right: companies must file separately in each EU member state where they want protection, and each national patent office makes its own determination.<\/p>\n\n\n\n

The SPC extends the protection of the basic patent for a product that has received a marketing authorization in the Community. The duration of the SPC equals the period between the filing date of the basic patent and the date of the first marketing authorization in the Community, reduced by five years. The maximum extension is five years. A Paediatric Extension of six months can be added if the company has conducted pediatric studies in compliance with an agreed Pediatric Investigation Plan (PIP).<\/p>\n\n\n\n

The ‘first marketing authorization in the Community’ language has generated decades of litigation. The relevant date is the date of the first authorization anywhere in the European Community\/Union, not the date of authorization in each individual member state. A company that received marketing authorization in Germany in January and France in March files for SPCs in both countries using the January date.<\/p>\n\n\n\n

Post-Brexit, the United Kingdom created its own SPC system that essentially mirrors the EU framework but treats UK marketing authorization dates as the trigger. Companies now manage separate timelines for GB, Northern Ireland (which has its own complexities under the Windsor Framework), and the EU.<\/p>\n\n\n\n

The Basic Patent Requirement<\/strong><\/h4>\n\n\n\n

The EU SPC system requires that the product be ‘protected by a basic patent in force.’ This seemingly simple requirement has produced what is arguably the most complex and expensive body of pharmaceutical patent litigation in European history.<\/p>\n\n\n\n

For a patent to qualify as the basic patent for an SPC, it must protect the product, either as such or as a product obtained by a certain process or as a use. The Court of Justice of the European Union (CJEU) has issued a series of rulings attempting to define exactly what ‘protects’ means in this context, and each ruling has generated further questions.<\/p>\n\n\n\n

The Teva v. Gilead case (C-121\/17) in 2018 established the ‘infringement test’: the basic patent must protect the product in the sense that the product must fall within the protection conferred by the patent, as interpreted in light of the description and drawings. The product must be specifically identifiable, in light of all the information disclosed by the patent, by a person skilled in the art at the filing date of the patent [5].<\/p>\n\n\n\n

This ruling created significant problems for combination product SPCs, where companies had obtained patents covering a broad class of compounds and then later obtained marketing authorization for a specific combination of two compounds. National courts in Germany, the Netherlands, and the UK reached different conclusions about whether the same patent qualified as the basic patent under different factual scenarios.<\/p>\n\n\n\n

The CJEU attempted further clarification in Royalty Pharma (C-650\/17) and Siemens Healthineers (C-673\/18) in 2020, but practitioners widely acknowledge that the framework remains difficult to apply with certainty in novel situations.<\/p>\n\n\n\n

The Japan PTE System<\/strong><\/h3>\n\n\n\n

Japan’s patent term extension system under Article 67(2) of the Patent Act compensates for the time lost during pharmaceutical regulatory review by the Pharmaceuticals and Medical Devices Agency (PMDA). The maximum extension is five years, and the calculation uses the period from patent filing to drug approval.<\/p>\n\n\n\n

Japan’s system is notable for allowing multiple patents covering the same product to each receive separate extensions, unlike the U.S. single-patent limitation. This makes Japan an exceptionally important jurisdiction for portfolio extension strategy: a company might extend a composition of matter patent, a formulation patent, and a method of treatment patent all covering the same drug.<\/p>\n\n\n\n

The Japan Patent Office (JPO) has been stricter than some other jurisdictions in requiring that the patent ‘required’ the regulatory approval period, i.e., that the patent actually covers the approved product in its approved form. Extension applications for patents with very broad claims that sweep up many compounds beyond the approved drug face more scrutiny.<\/p>\n\n\n\n

Canada: The NOC System and Section 37 Extensions<\/strong><\/h3>\n\n\n\n

Canada’s patent extension mechanism under the Patent Act, specifically Section 37, allows for extensions for patents covering drugs that received a Notice of Compliance (NOC) from Health Canada. The Canadian system was substantially reformed by the Canada-United States-Mexico Agreement (CUSMA\/USMCA) implementation, which obligated Canada to provide patent term adjustments for unreasonable delays in patent prosecution.<\/p>\n\n\n\n

Canada also operates the Patented Medicines (Notice of Compliance) Regulations, commonly called the PM(NOC) Regulations, which create a linkage system between drug approvals and patent listings. Understanding which patents are listed on the Patent Register and their expiration dates is critical for both brand and generic companies operating in Canada.<\/p>\n\n\n\n

Australia: Pharmaceutical Patents and Extensions of Term<\/strong><\/h3>\n\n\n\n

Australia’s pharmaceutical patent extension system under Chapter 6 of the Patents Act 1990 permits an extension of up to five years for pharmaceutical substance patents where regulatory approval by the Therapeutic Goods Administration (TGA) has delayed commercial exploitation. The calculation compares the TGA approval date against the patent filing date and a reference point fifteen years after filing, with the extension limited by this formula.<\/p>\n\n\n\n

Australia is increasingly important in global patent strategy not just because of its own market but because Australian Patent Office decisions and Federal Court judgments on extension applications have occasionally influenced thinking in other common law jurisdictions.<\/p>\n\n\n\n

\n\n\n\n

Part Two: Tracking the Key Regulatory Dates<\/strong><\/h2>\n\n\n\n

The IND Effective Date: Foundation of the U.S. PTE Calculation<\/strong><\/h3>\n\n\n\n

The IND effective date is not the date the company submits the IND application to the FDA. It is the date thirty days after submission, unless the FDA places the study on clinical hold before that thirty-day period expires. This distinction matters because companies sometimes conflate the submission date with the effective date in their PTE calculations.<\/p>\n\n\n\n

FDA regulations at 21 C.F.R. \u00a7 312.40 specify that an IND takes effect thirty days after FDA receives the application unless the FDA notifies the sponsor that the investigation is subject to a clinical hold. Companies should record the IND submission date and then note the IND effective date as thirty days later, unless a clinical hold intervened.<\/p>\n\n\n\n

For drugs developed initially by academic institutions or small biotechs before acquisition by larger pharmaceutical companies, tracing the original IND effective date can require document archaeology. The IND number, which is publicly available through the FDA’s database, anchors this search, but the actual submission date may be held in records that transferred hands during acquisitions, sometimes multiple times.<\/p>\n\n\n\n

Protocol Amendments and Multiple INDs<\/strong><\/h4>\n\n\n\n

Many drugs have not one IND but multiple INDs covering different indications or different formulations. The PTE calculation uses the IND filing date for the approved indication, not necessarily the earliest IND filed for the compound. If a company filed an IND for Indication A in 2005 and a separate IND for Indication B in 2008, and the NDA approval covers Indication B, the 2008 IND date governs the PTE calculation for patents covering Indication B.<\/p>\n\n\n\n

This creates situations where the choice of which indication to prioritize in development affects the eventual patent extension. Companies that understand this connection make explicit decisions; companies that do not may be surprised by shorter-than-expected extensions.<\/p>\n\n\n\n

The NDA\/BLA Filing Date<\/strong><\/h3>\n\n\n\n

The NDA or BLA filing date is the date the FDA receives the application, not the date the application is accepted for review (which is the ‘filing date’ in a procedural sense under FDA’s review clock rules, but different from the receipt date for PTE calculation purposes).<\/p>\n\n\n\n

The FDA issues a Refuse to File (RTF) letter if the application is not sufficiently complete. If the company refiles, the refiling date becomes the relevant date for PTE purposes. Companies that receive RTF letters and refile have sometimes been caught off guard by how this resets their PTE calculation.<\/p>\n\n\n\n

Complete Response Letters (CRLs), in which the FDA finds the application otherwise complete but requires additional information before approval, do not reset the filing date in the same way. However, the period during which the company is responding to a CRL may be deemed an applicant delay period if the FDA later determines the company did not act with due diligence.<\/p>\n\n\n\n

The NDA\/BLA Approval Date<\/strong><\/h3>\n\n\n\n

The FDA approval date is the date of the approval letter, not the date the product launches commercially. For PTE purposes, the approval date is clear and unambiguous. For SPC purposes in the EU, the relevant date is the date of the marketing authorization (MA) decision, which may differ from the date the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issues its positive opinion.<\/p>\n\n\n\n

The EU marketing authorization, for centralized procedure drugs, is issued by the European Commission based on the CHMP opinion. The Commission decision date is the date used for SPC calculations. For nationally authorized products, the national competent authority decision date applies.<\/p>\n\n\n\n

Companies operating globally typically maintain what are called ‘regulatory milestone calendars’ that track, for every product in development, the IND date (U.S.), CTA dates (Clinical Trial Authorization dates for EU), NDA\/BLA filing date, CHMP opinion date, EC decision date, and national MA dates in each relevant jurisdiction. When an NDA approval comes in, the legal and regulatory teams should already have computed tentative PTE and SPC deadlines.<\/p>\n\n\n\n

The Sixty-Day U.S. PTE Filing Window<\/strong><\/h3>\n\n\n\n

The requirement to file a PTE application within sixty days of FDA approval operates with complete rigidity. The Federal Circuit confirmed in Univ. of Rochester v. G.D. Searle & Co. (2003) and subsequent cases that the sixty-day window is a statutory requirement, not a procedural one, and that equitable tolling does not apply.<\/p>\n\n\n\n

Sixty days sounds comfortable until you consider that it runs during what is typically the most chaotic period in a drug launch: commercial launch preparation, media relations, investor calls, managed care contracting, and distribution logistics. IP teams that do not have their PTE application substantially drafted before FDA approval chase the deadline while competing against every other operational priority of the launch.<\/p>\n\n\n\n

Best practice is to have the PTE application drafted and internally approved no later than NDA acceptance, so that the team spends the post-approval sixty days in final review rather than drafting from scratch.<\/p>\n\n\n\n

Selecting the Patent: The Stakes of the Choice<\/strong><\/h4>\n\n\n\n

When filing the PTE application, the company designates a single patent. The decision requires modeling several scenarios:<\/p>\n\n\n\n

First, which patent has the longest base expiration date? A patent expiring in 2032 extended by three years gives protection through 2035. A patent expiring in 2030 extended by five years (the statutory maximum) gives protection through 2035. They are identical in outcome if the calculations work that way, but the base expiration dates may be different enough that the choice is not obvious.<\/p>\n\n\n\n

Second, which patent covers the commercial product with the least vulnerability to validity challenge? Generic manufacturers file Paragraph IV certifications against listed patents, asserting invalidity or non-infringement. A composition of matter patent on a small molecule is generally harder to design around than a formulation patent. Choosing the strongest patent for extension maximizes the value of the protection.<\/p>\n\n\n\n

Third, are there method of use patents that cover only specific approved indications, with later expiration dates, where a shorter extension might still provide the most valuable coverage? Some drugs are approved for multiple indications over time. The first-approved indication may be the less commercially valuable one.<\/p>\n\n\n\n

Sophisticated IP teams model all three of these dimensions simultaneously. DrugPatentWatch is one of the tools practitioners use to review competitor patent landscapes and reverse-engineer how competitors made analogous patent selection decisions, giving benchmarks for the analysis.<\/p>\n\n\n\n

\n\n\n\n

Part Three: The SPC Application Calendar Across Jurisdictions<\/strong><\/h2>\n\n\n\n

EU SPC Filing Deadlines<\/strong><\/h3>\n\n\n\n

The SPC application in each EU member state must be filed within six months of the grant of the marketing authorization in the Community or within six months of the grant of the basic patent, whichever is later. This six-month window differs from the U.S. sixty-day window and is slightly more manageable, but companies pursuing protection across all EU member states simultaneously face the challenge of coordinating filings through local patent attorneys in twenty-seven jurisdictions.<\/p>\n\n\n\n

Post-Brexit, the UK runs its own parallel six-month window from UK marketing authorization. Given that the UK granted its own MAs separately from the EU after January 1, 2021, the UK window often runs on a different calendar than the EU window.<\/p>\n\n\n\n

For products authorized through the centralized procedure, which covers most new biologics and products for diseases like HIV, cancer, diabetes, and neurodegenerative conditions, the EC decision date is the trigger. For nationally authorized products, each country’s MA date applies independently.<\/p>\n\n\n\n

The Paediatric Extension: The Six-Month Bonus<\/strong><\/h4>\n\n\n\n

A critical additional element of the EU SPC system is the Paediatric Extension. Under Article 36 of Regulation (EC) No. 1901\/2006, an SPC can be extended by six months if the marketing authorization holder has conducted studies in the pediatric population in compliance with an agreed PIP, and those studies are reflected in the product information.<\/p>\n\n\n\n

The Paediatric Extension requires a separate application to the national patent office after the basic SPC is granted, within a specific window. The extension applies even if the pediatric studies showed that the drug does not work in children or that dosing is similar to adults. What matters is that the studies were completed and reflected in the label.<\/p>\n\n\n\n

For high-revenue drugs where the SPC represents billions in protected cash flow, six additional months of European exclusivity can be worth anywhere from $500 million to over $2 billion depending on market size, pricing, and the pace of biosimilar or generic entry. Companies that skip the PIP process, or that complete pediatric studies but fail to reflect the results in the label update required to trigger the extension, forfeit that value.<\/p>\n\n\n\n

The PIP must be agreed with the EMA’s Pediatric Committee (PDCO) before the clinical development program concludes. This means companies need to factor the PIP obligation and opportunity into their clinical development planning years before NDA\/MA filing, not as an afterthought when the SPC application is being prepared.<\/p>\n\n\n\n

Germany: The National Patent Office and CJEU Compliance<\/strong><\/h3>\n\n\n\n

The German Patent and Trade Mark Office (DPMA) is one of the busiest SPC filing destinations in Europe and has historically been among the more technically demanding. German SPC examination is thorough, and the DPMA has sometimes issued provisional refusals pending CJEU rulings on interpretation questions.<\/p>\n\n\n\n

Germany is also one of the most important patent litigation venues in Europe. The D\u00fcsseldorf, Mannheim, and Munich regional courts each handle large volumes of pharmaceutical patent cases, and their judges are considered among the most expert in Europe on pharma IP questions. An SPC granted by the DPMA will be litigated, if at all, through these courts.<\/p>\n\n\n\n

The German courts’ interpretation of the CJEU’s SPC jurisprudence has sometimes diverged from other national courts, particularly on combination product cases. Companies filing SPCs for products covered by combination patents in Germany should anticipate scrutiny of the basic patent requirement and prepare detailed claim charts mapping the patent claims to the approved product.<\/p>\n\n\n\n

The Netherlands: A Battleground for SPC Validity<\/strong><\/h3>\n\n\n\n

The Netherlands has become one of Europe’s primary venues for SPC validity challenges, partly because Dutch courts hear cases on an accelerated schedule and partly because the Dutch courts have historically been willing to grant pan-European provisional injunctions in appropriate cases. Challengers, typically generic manufacturers, have used Dutch proceedings to test SPC validity across multiple jurisdictions simultaneously.<\/p>\n\n\n\n

The Rechtbank Den Haag (Hague District Court) and the Court of Appeal of The Hague handle most pharmaceutical IP cases. Dutch courts have issued significant SPC decisions on the basic patent requirement, on the ‘first authorization in the Community’ question for products that received earlier authorization in non-EU countries like Switzerland, and on procedural questions about when SPC applications can be amended.<\/p>\n\n\n\n

France, Italy, Spain: The Southern European SPC Markets<\/strong><\/h3>\n\n\n\n

France, Italy, and Spain represent large prescription drug markets and essential SPC filings for any global pharmaceutical company. All three countries follow the EU SPC regulation but have specific procedural requirements for filing.<\/p>\n\n\n\n

France’s Institut National de la Propri\u00e9t\u00e9 Industrielle (INPI) handles French SPC applications. Italy’s Ufficio Italiano Brevetti e Marchi (UIBM) handles Italian filings. Spain’s Oficina Espa\u00f1ola de Patentes y Marcas (OEPM) handles Spanish filings.<\/p>\n\n\n\n

Each of these offices has local-language filing requirements, local attorney requirements, and local fee schedules. Coordination across Southern Europe requires a network of local patent attorneys in each country, typically managed by the company’s primary European IP counsel from the UK, Germany, or Switzerland.<\/p>\n\n\n\n

Italy has been notable for specific SPC disputes involving the timing of the ‘first authorization in the Community’ for products where the development history included authorizations in older member states before the current regulation’s effective date.<\/p>\n\n\n\n

UK Post-Brexit SPC Strategy<\/strong><\/h3>\n\n\n\n

The UK’s departure from the EU created a bifurcation that pharmaceutical companies are still navigating. From January 1, 2021, the UK Intellectual Property Office (UKIPO) administers a standalone SPC system. UK SPCs filed after that date are based on UK marketing authorization dates and are governed by domestic UK regulations that mirror, but are no longer legally synchronized with, EU SPC regulations.<\/p>\n\n\n\n

For products where the EU marketing authorization was converted into a UK MA on January 1, 2021 under the grandfathering provisions, the relevant date for calculating UK SPC duration may be the original EU authorization date, not the date of UK conversion. The UKIPO issued guidance on this question but practitioners continue to find edge cases.<\/p>\n\n\n\n

Northern Ireland presents additional complexity. Under the Windsor Framework (which revised the original Northern Ireland Protocol), Northern Ireland follows EU rules for goods, which has implications for pharmaceutical products and potentially for SPC protection in Northern Ireland specifically. This remains an actively developing area of law.<\/p>\n\n\n\n

The UK has signaled its intention to reform its SPC system and potentially introduce a Regulatory Data Protection mechanism that differs from the EU’s approach. Any such reform would affect how companies model UK exclusivity going forward.<\/p>\n\n\n\n

Japan: Filing Timelines and the JPO Review Process<\/strong><\/h3>\n\n\n\n

The Japan Patent Office review of PTE applications is thorough and can take eighteen to twenty-four months from filing. Japanese PTE applications must be filed within three months of the drug approval (shonin) by the PMDA, a shorter window than either the U.S. or EU systems.<\/p>\n\n\n\n

Japan’s system allows multiple PTEs on the same product, as noted above, making portfolio management particularly important. Companies that fail to file PTEs for all eligible patents within the three-month window permanently lose that extension opportunity for those patents.<\/p>\n\n\n\n

The JPO has become more rigorous in requiring documentary evidence of the regulatory review period, including records of PMDA communications, clinical data submission timelines, and approval decisions. Companies that maintain meticulous regulatory files in Japan throughout the review process are better positioned to support their extension applications.<\/p>\n\n\n\n

Canada: CUSMA Implementation and Patent Term Adjustment<\/strong><\/h3>\n\n\n\n

Canada’s CUSMA obligations required significant reform of its patent system, including the introduction of a patent term adjustment (PTA) mechanism for patents delayed by prosecution at the Canadian Intellectual Property Office (CIPO). This PTA is separate from the pharmaceutical PTE available under Section 37 for drug approvals.<\/p>\n\n\n\n

Under Section 37, the extension compensates for the period between Health Canada’s market authorization under the Food and Drug Act and the end of what would otherwise be the patent term, subject to a two-year cap in most cases. Unlike the U.S. system’s five-year maximum, Canada’s limit of two years makes the Canadian extension substantially less valuable in many cases, though still commercially significant for high-revenue drugs.<\/p>\n\n\n\n

Canada’s PM(NOC) Regulations create a separate, parallel system for listing patents on the Patent Register and linking those listings to the generic drug approval process. This linkage system affects generic entry timing independently of the patent term extension framework.<\/p>\n\n\n\n

Australia: The Federal Court and Extension Litigation<\/strong><\/h3>\n\n\n\n

Australia’s extension of term system has generated a significant body of Federal Court jurisprudence on what constitutes a ‘pharmaceutical substance per se’ eligible for extension, the calculation of the extension period, and whether formulation patents qualify alongside composition of matter patents.<\/p>\n\n\n\n

The maximum extension in Australia is five years, calculated using the formula: extension = approval date minus patent filing date minus fifteen years. If the drug was approved more than fifteen years after the patent was filed, no extension is available. If it was approved exactly fifteen years after filing, the extension is zero. The formula rewards drugs where the regulatory review period was exceptionally long relative to the fifteen-year reference point.<\/p>\n\n\n\n

The Therapeutic Goods Administration (TGA) certifies the relevant regulatory dates. Companies must file for extension within six months of TGA approval. The IP Australia office makes the final determination.<\/p>\n\n\n\n

\n\n\n\n

Part Four: Data Management and the Competitive Intelligence Layer<\/strong><\/h2>\n\n\n\n

The Regulatory Date Tracking Infrastructure<\/strong><\/h3>\n\n\n\n

Pharmaceutical IP departments at large companies typically maintain dedicated databases that track, for every approved and investigational product, the full set of regulatory milestone dates across all relevant jurisdictions. These databases feed into automated deadline systems that generate alerts and action items months before filing deadlines.<\/p>\n\n\n\n

The inputs to these databases include:<\/p>\n\n\n\n

    \n
  • FDA IND numbers and effective dates (U.S.)<\/li>\n\n\n\n
  • Clinical Trial Authorization numbers and dates (EU, UK)<\/li>\n\n\n\n
  • NDA\/BLA filing and approval dates (U.S.)<\/li>\n\n\n\n
  • CHMP opinion dates and EC decision dates (EU)<\/li>\n\n\n\n
  • MHRA approval dates (UK)<\/li>\n\n\n\n
  • PMDA approval dates (Japan)<\/li>\n\n\n\n
  • Health Canada NOC dates (Canada)<\/li>\n\n\n\n
  • TGA approval dates (Australia)<\/li>\n<\/ul>\n\n\n\n

    For each jurisdiction, the database outputs the SPC or PTE application deadline, the calculated maximum extension duration, the earliest possible expiration date with and without extension, and the internal assignment of responsibility for the application filing.<\/p>\n\n\n\n

    Companies that have centralized this infrastructure have a meaningful operational advantage over those that manage these dates through fragmented systems. The cost of a missed deadline in any single major jurisdiction can easily exceed the cost of years of database maintenance.<\/p>\n\n\n\n

    Using Public Patent Databases for Competitive Intelligence<\/strong><\/h3>\n\n\n\n

    Beyond tracking your own products, tracking competitor products’ regulatory dates and patent landscapes is standard competitive intelligence practice. DrugPatentWatch aggregates patent expiration data, SPC status information, Paragraph IV challenge filings, and regulatory exclusivity data across thousands of drugs, making it one of the primary tools analysts use to map the competitive landscape.<\/p>\n\n\n\n

    By examining the patent expiration dates and extension applications for competitor products, companies can:<\/p>\n\n\n\n

      \n
    • Estimate when branded competitors will face generic entry, informing market share projections<\/li>\n\n\n\n
    • Identify gaps in competitor patent portfolios that might be exploited through generic or biosimilar development<\/li>\n\n\n\n
    • Benchmark their own patent strategy decisions against analogous competitor situations<\/li>\n\n\n\n
    • Monitor for new Paragraph IV challenges against their own products that might signal imminent generic entry attempts<\/li>\n<\/ul>\n\n\n\n

      Investment analysts covering pharmaceutical companies use similar data to model revenue cliffs associated with patent expiries, which affects stock valuations and M&A premiums. Understanding that data is available and how it is used creates a strategic consideration for how pharmaceutical companies file and manage their patent portfolios. <blockquote> ‘Generic drug entry following patent expiration reduces brand revenue by an average of 85 to 90 percent within twelve months in the U.S. market, with biosimilar entry for biologics generating slower but ultimately comparable erosion over a two-to-five year period.’ \u2014 IQVIA Institute for Human Data Science, Medicine Use and Spending in the U.S., 2023 [6] <\/blockquote><\/p>\n\n\n\n

      The Freedom to Operate Analysis and Its Intersection with Extension Monitoring<\/strong><\/h3>\n\n\n\n

      For generic and biosimilar manufacturers, monitoring competitor PTE and SPC applications is not passive intelligence gathering. It directly determines the commercial entry date for their own products.<\/p>\n\n\n\n

      When an SPC is granted in Germany for a drug that would otherwise have lost protection in 2027, the generic manufacturer cannot launch in Germany until the SPC expires, which might be 2031. If the SPC is vulnerable to validity challenge, the generic manufacturer may invest in litigation to invalidate it. If the SPC is clearly valid, the launch plan shifts entirely.<\/p>\n\n\n\n

      This creates a dynamic where generic manufacturers have strong incentives to monitor PTE and SPC applications in real time, not just at the time of their own regulatory filing. Services like DrugPatentWatch provide feeds of new SPC applications and PTE filings, allowing generic manufacturers to build their entry timeline models continuously rather than reconstructing the landscape at the time of ANDA or biosimilar filing.<\/p>\n\n\n\n

      \n\n\n\n

      Part Five: Major Litigation Shaping the Rules<\/strong><\/h2>\n\n\n\n

      Gilead v. Teva and the Combination Product Problem<\/strong><\/h3>\n\n\n\n

      The 2018 CJEU ruling in Teva UK Ltd v. Gilead Sciences Inc. (C-121\/17) addressed the question of whether a patent claiming a compound X could serve as the basic patent for an SPC covering a combination product X+Y, where Y was neither claimed in the patent nor described as part of the combination [7].<\/p>\n\n\n\n

      The court’s answer was effectively no: the combination X+Y had to be specifically identifiable in the patent as filed, in the sense that the patent had to relate to it as part of its subject matter. The claim merely claiming compound X was not sufficient.<\/p>\n\n\n\n

      This ruling invalidated or threatened SPC applications across Europe for several important HIV and antiviral drugs, particularly in cases where a company had obtained a broad early patent claiming an entire class of compounds and then later developed a combination product containing one of those compounds.<\/p>\n\n\n\n

      Gilead’s SPC for Truvada (tenofovir disoproxil + emtricitabine) was directly at issue. The combination patent disclosed both compounds, but generic manufacturers argued it did not specifically identify the combination. The CJEU’s ruling and subsequent national court decisions effectively ended Truvada’s European SPC protection earlier than Gilead had anticipated.<\/p>\n\n\n\n

      The litigation spawned parallel proceedings in Germany, the UK, the Netherlands, France, and Italy, with some national courts reaching different conclusions about how to apply the CJEU test on specific facts. The resulting legal uncertainty continues to affect how companies draft combination product patents today: the lesson was that patents claiming combinations need to explicitly describe and claim the specific combination, not just the individual components.<\/p>\n\n\n\n

      AstraZeneca and the Regulatory Gaming Controversy<\/strong><\/h3>\n\n\n\n

      AstraZeneca’s conduct involving omeprazole (Losec\/Prilosec) patent protection in Europe generated one of the most consequential competition law investigations in pharmaceutical IP history. The European Commission found in 2005 that AstraZeneca had abused its dominant position by making misleading representations to patent offices in several EU member states about the date of the ‘first authorization in the Community’ for omeprazole, in order to obtain SPCs it was not entitled to or to obtain longer SPCs than the law permitted [8].<\/p>\n\n\n\n

      The abuse consisted of representing that the relevant ‘first authorization’ date was the date on which the marketing authorization was published in the official journal of a member state, rather than the date the authorization was actually granted. By using the later publication date as the reference point, AstraZeneca obtained additional months of SPC coverage.<\/p>\n\n\n\n

      The General Court and the Court of Justice upheld the Commission’s finding and its fine, confirming that making false or misleading representations to patent offices in the context of SPC applications can constitute an abuse of dominant position under Article 102 TFEU.<\/p>\n\n\n\n

      The AstraZeneca case established that while companies have the right to apply for legitimate extensions of their intellectual property rights, they cannot misrepresent the regulatory facts supporting those applications. It also put a spotlight on the accuracy of date representations in SPC filings, leading companies to establish more rigorous internal verification processes for the regulatory dates they cite.<\/p>\n\n\n\n

      Warner-Chilcott v. Teva (U.S. PTE Disputes)<\/strong><\/h3>\n\n\n\n

      The United States has generated its own body of PTE litigation, though it is less voluminous than the EU SPC litigation. Warner-Chilcott’s extension applications for its hormone therapy products generated disputes about the calculation of applicant delays and the proper identification of the regulatory review period.<\/p>\n\n\n\n

      The underlying tensions are consistent across cases: patent holders want the longest possible extension and tend to minimize the attributable delay periods; generic manufacturers challenge extensions to accelerate entry; and the USPTO and FDA apply the statutory formula with varying degrees of rigor in specific situations.<\/p>\n\n\n\n

      One recurring issue involves drugs that had clinical testing conducted under multiple INDs for multiple indications. When the approved product covers only one of those indications, questions arise about whether clinical testing time for other indications counts as part of the regulatory review period that the PTE is supposed to compensate.<\/p>\n\n\n\n

      The Unitary Patent and SPC Reform in Europe<\/strong><\/h3>\n\n\n\n

      The European Unitary Patent system, which became operational in June 2023, created a new patent title that provides uniform protection across all participating EU member states through a single grant from the European Patent Office (EPO). This development has significant implications for SPC strategy.<\/p>\n\n\n\n

      Currently, a Unitary Patent can serve as the basic patent for SPC applications, but the SPC itself remains a national right filed in each country separately. The European Commission has been studying a Unitary SPC system that would grant protection uniformly across member states through a single filing, analogous to how the Unitary Patent works.<\/p>\n\n\n\n

      A Unitary SPC would dramatically simplify the filing process and reduce the legal costs of maintaining twenty-seven separate SPC applications. It would also eliminate the fragmented enforcement landscape where SPC validity is determined differently in different countries. The Commission’s consultation on this reform has generated extensive industry input, and reform legislation is expected in the coming years.<\/p>\n\n\n\n

      Companies with major SPC filings approaching should monitor this reform closely. If a Unitary SPC system is implemented, the filing strategy for extensions of patents granted or converting to Unitary Patent status may need to change.<\/p>\n\n\n\n

      \n\n\n\n

      Part Six: Biologics, Biosimilars, and the Extension Puzzle<\/strong><\/h2>\n\n\n\n

      Why Biologics Are Different<\/strong><\/h3>\n\n\n\n

      Patent extension strategy for biologics (large molecule drugs like monoclonal antibodies, fusion proteins, and recombinant hormones) operates on fundamentally different ground than small molecule strategy.<\/p>\n\n\n\n

      Biologics patents are numerous, complex, and typically cover multiple levels: the composition of matter of the molecule itself (often protected by multiple patents claiming the antibody sequence, the variable region, or the CDRs), formulation patents, manufacturing process patents, dosing patents, and method of treatment patents. A single biologic may have thirty to sixty patents listed in the Orange Book (for drugs that fit its parameters) or in internal IP registers.<\/p>\n\n\n\n

      Only one U.S. patent receives a PTE. In Europe, multiple SPCs can be filed in each country, but each SPC must reference a specific basic patent and cover a specific ‘product.’ The definition of ‘product’ in the SPC regulation for biologics has been contested: is the antibody itself the product, or is a specific formulation of the antibody a different product eligible for its own SPC?<\/p>\n\n\n\n

      The CJEU addressed this question in part through its rulings on ‘product,’ holding that a medicinal product is not the same thing as a ‘product’ within the meaning of the SPC regulation simply because it is authorized for a new use. A new clinical use of the same molecule does not give rise to a new SPC if an SPC has already been granted for that molecule [9].<\/p>\n\n\n\n

      Biosimilar Competition and the Exclusivity Clock<\/strong><\/h3>\n\n\n\n

      Biosimilars compete with reference biologics on a different timeline than small molecule generics compete with brand drugs. Regulatory pathway exclusivities under the Biologics Price Competition and Innovation Act (BPCIA) in the U.S. include twelve years of reference product exclusivity and four years of data exclusivity. These exclusivities run independently of patent protection and sometimes provide more commercially relevant protection than the underlying patents.<\/p>\n\n\n\n

      Outside the U.S., the EU’s data exclusivity period for biologics is eight years of data protection plus two years of market exclusivity (the 8+2 formula), sometimes extended by one additional year for a new indication. Understanding how these regulatory exclusivities interact with SPC protection requires mapping both systems simultaneously.<\/p>\n\n\n\n

      For biosimilar manufacturers, the entry timing analysis requires comparing the SPC expiration date (or the absence of an SPC) against the reference product exclusivity date and the data exclusivity date. Entry is only commercially viable after all three forms of protection expire, or after a successful legal challenge to one or more of them.<\/p>\n\n\n\n

      Adalimumab: A Case Study in Biologic Patent Defense<\/strong><\/h3>\n\n\n\n

      AbbVie’s Humira (adalimumab) represents the most extensively documented case of biologic patent defense strategy in pharmaceutical history. At peak, AbbVie held over 130 patents related to adalimumab, covering the molecule, its formulations, dosing regimens, methods of manufacture, and specific uses [10].<\/p>\n\n\n\n

      In Europe, biosimilar competition began in October 2018 when the SPC protecting the basic antibody composition patent expired. AbbVie did not have SPC protection extending all European patents to the same date, and the expiration of the fundamental composition SPC opened the door for biosimilar entry across the EU.<\/p>\n\n\n\n

      In the United States, biosimilar competition was delayed until 2023, when a series of settlement agreements allowed several biosimilar manufacturers to enter the market on agreed dates. AbbVie received a U.S. PTE on one of its core Humira patents that contributed to the delayed entry timeline.<\/p>\n\n\n\n

      The Humira experience shaped biosimilar and biologic company patent strategy for the subsequent decade. It demonstrated that a sufficiently dense patent portfolio can delay competition for years beyond the expiration of the fundamental composition patents, and it prompted both regulatory and legislative scrutiny of ‘patent thickets’ in biologics.<\/p>\n\n\n\n

      The FTC, under both the Obama and Biden administrations, criticized biologic patent thickets and their interaction with the biosimilar pathway. Congressional proposals including the BIOSIM Act sought to limit the number of patents that can be asserted in BPCIA litigation. These policy developments are ongoing and could affect the value of certain biologic patent portfolios going forward.<\/p>\n\n\n\n

      \n\n\n\n

      Part Seven: Practical Mechanics of the Application Process<\/strong><\/h2>\n\n\n\n

      The U.S. PTE Application: What Goes In<\/strong><\/h3>\n\n\n\n

      A U.S. PTE application under 37 C.F.R. \u00a7 1.710 et seq. requires the following core elements:<\/p>\n\n\n\n

      The applicant identifies the patent number, the patent claims the applicant is relying on (the claims that cover the approved product), and the regulatory review period for which compensation is claimed. The applicant submits a copy of the FDA approval letter, the IND filing date (or the date of the earliest IND filing that formed the basis of the NDA), the NDA filing date, the NDA approval date, and a calculation of the regulatory review period based on these dates.<\/p>\n\n\n\n

      The applicant also must submit a declaration that the patent qualifies for extension (only one extension per patent, first commercial marketing approval, etc.) and that the applicant acted with due diligence throughout the regulatory review period.<\/p>\n\n\n\n

      The PTO publishes the PTE application in the Official Gazette and in its Patent Term Extension database. Generic manufacturers and other interested parties can file comments within a specified period. The FDA then conducts its own review of the regulatory review period and issues a Determination of Regulatory Review Period, which the PTO uses to calculate the final extension.<\/p>\n\n\n\n

      If there are disputes about the regulatory review period determination, the applicant or interested parties can petition for due diligence review. Due diligence petitions require detailed documentation of all regulatory interactions during the review period, essentially a chronological reconstruction of all actions taken (and their timing) from IND filing to NDA approval.<\/p>\n\n\n\n

      The EU SPC Application Process<\/strong><\/h3>\n\n\n\n

      Each EU member state SPC application requires:<\/p>\n\n\n\n

        \n
      • Identification of the basic patent<\/li>\n\n\n\n
      • The number and date of the marketing authorization (and a copy)<\/li>\n\n\n\n
      • A brief summary of the invention (typically drawn from the patent specification)<\/li>\n\n\n\n
      • The name and address of the holder of the marketing authorization<\/li>\n\n\n\n
      • The national filing fee<\/li>\n<\/ul>\n\n\n\n

        Some member states require additional documentation, such as translations of the marketing authorization into the national language, translations of patent claims, or formal powers of attorney. German filings, for instance, have historically required detailed German-language documentation that purely English-speaking legal teams need local counsel to prepare.<\/p>\n\n\n\n

        After filing, the national patent office examines whether the formal requirements are met and whether the substantive conditions for SPC grant are satisfied. In most member states, examination is relatively ministerial for straightforward applications: if you have a valid basic patent and a marketing authorization for the same product, the SPC issues. Complications arise for combination products, biologics, and products where the ‘first authorization in the Community’ question is not straightforward.<\/p>\n\n\n\n

        Tracking Applications Through National Registers<\/strong><\/h3>\n\n\n\n

        Every EU member state maintains a public register of SPCs. The EP’s European Patent Register includes some SPC information, but comprehensive coverage requires checking each national register. Services like DrugPatentWatch aggregate SPC register data from multiple jurisdictions, making it practical to monitor the SPC status of multiple products across Europe simultaneously.<\/p>\n\n\n\n

        For competitive intelligence purposes, monitoring when SPCs are filed, granted, and contested in the registers gives advance visibility into competitor exclusivity timelines. A company entering the biosimilar market for Drug X needs to know not just when Drug X’s primary patents expire but whether Drug X has SPCs in Germany, France, Italy, Spain, and the UK that push the effective expiry date out by up to five years plus a potential six-month pediatric extension.<\/p>\n\n\n\n

        Maintenance and Renewal of SPCs<\/strong><\/h3>\n\n\n\n

        SPCs in most EU member states require annual renewal fees during their term, separate from the annual fees for the underlying patent. Companies must maintain these renewals or the SPC lapses. For high-revenue drugs, this is not a meaningful financial consideration, but for products that have lost revenue before the SPC expires (perhaps because the drug was superseded by a newer treatment), the question of whether to maintain the SPC renewals can arise.<\/p>\n\n\n\n

        Inadvertent SPC lapse due to missed renewal fees can, in some jurisdictions, be remedied through restoration procedures, but these are not automatic and may require showing that the failure to pay was unintentional. Companies with large portfolios spanning many jurisdictions use IP management software with automated renewal tracking to prevent this scenario.<\/p>\n\n\n\n

        \n\n\n\n

        Part Eight: The Business Case for Extension Optimization<\/strong><\/h2>\n\n\n\n

        Quantifying the Value of Each Additional Month<\/strong><\/h3>\n\n\n\n

        The financial value of a PTE or SPC depends on three variables: the drug’s annual net revenue in the relevant market, the time remaining in the extension period, and the assumed erosion rate once the extension expires.<\/p>\n\n\n\n

        For a drug generating $3 billion in annual U.S. net revenue, with a 90 percent first-year erosion assumption, the value of twelve months of PTE protection is roughly $2.7 billion in avoided revenue loss (treating the revenue during the extension period as fully protected and the post-extension period as experiencing the 90 percent erosion). For five years of maximum extension, the cumulative value can approach $10 billion, discounted back to present value.<\/p>\n\n\n\n

        These numbers explain why pharmaceutical companies invest heavily in IP departments, in outside counsel for PTE and SPC prosecution, and in litigation to defend granted extensions against generic challenges. The return on investment for a patent law team that successfully defends a five-year SPC in Germany for a $2 billion-per-year drug is essentially incalculable relative to the legal budget.<\/p>\n\n\n\n

        They also explain why generic manufacturers invest comparably in challenging SPCs and PTEs. Winning an SPC invalidity action in Germany might accelerate generic entry by three years and generate hundreds of millions of euros in first-mover generic revenue.<\/p>\n\n\n\n

        The Royalty Pharma Model and Market Dynamics<\/strong><\/h3>\n\n\n\n

        Royalty Pharma, one of the largest royalty aggregators in biopharmaceuticals, structures transactions that involve rights to royalty streams on drugs with active PTEs and SPCs. The value of those royalty streams depends directly on the duration of the exclusivity periods. When Royalty Pharma evaluates a royalty acquisition, its analysts model the PTE\/SPC dates with the same rigor as pharmaceutical company IP departments.<\/p>\n\n\n\n

        Similarly, when private equity firms evaluate acquisitions of branded pharmaceutical companies or product lines, patent extension status is a core element of the valuation model. A drug with five years of SPC protection remaining in Europe and three years of PTE remaining in the U.S. has a fundamentally different revenue profile than a drug whose protection expires in twelve months.<\/p>\n\n\n\n

        Investment bankers and analysts who do not have sophisticated capabilities to model patent expiry dates, including the possibility of PTE and SPC extensions, systematically misprice pharmaceutical assets. The difference between a correct and incorrect extension date assumption can shift a drug’s discounted cash flow value by 30 to 50 percent.<\/p>\n\n\n\n

        The Role of IP Due Diligence in M&A<\/strong><\/h3>\n\n\n\n

        When a large pharmaceutical company acquires a smaller company or licenses a drug in late-stage development, IP due diligence includes a specific workstream on extension eligibility. The due diligence team maps:<\/p>\n\n\n\n

          \n
        • The IND filing date for the lead product (and all clinical candidates)<\/li>\n\n\n\n
        • The earliest NDA filing date projection<\/li>\n\n\n\n
        • The projected approval date and its implications for PTE calculation<\/li>\n\n\n\n
        • The comparable analysis for EU SPC applications<\/li>\n\n\n\n
        • Whether the Pediatric Investigation Plan has been agreed and what the pediatric extension opportunity looks like<\/li>\n\n\n\n
        • Whether any clinical hold or applicant delay periods exist that would reduce the extension<\/li>\n<\/ul>\n\n\n\n

          For late-stage assets being acquired in Year 7 of clinical development, the IND date may already be established and the PTE calculation may be substantially deterministic. For assets being acquired in Year 2 or 3 of development, the extension analysis requires assumptions about development timeline.<\/p>\n\n\n\n

          Due diligence teams regularly discover that target companies have not managed their IND files in ways that maximize PTE eligibility. Common issues include:<\/p>\n\n\n\n

            \n
          • The original IND was filed for a different indication than the lead indication being acquired<\/li>\n\n\n\n
          • Clinical holds that were placed and lifted created periods that may be characterized as applicant delays<\/li>\n\n\n\n
          • The company made responses to FDA information requests that were unusually slow, creating potential applicant delay periods<\/li>\n\n\n\n
          • Multiple INDs were filed for overlapping purposes, and the relationship among them affects the extension calculation<\/li>\n<\/ul>\n\n\n\n

            In some cases, these findings reduce the value of the asset materially. In others, the acquiring company identifies opportunities the target had missed, such as the availability of extensions on specific patents that the target had not considered.<\/p>\n\n\n\n

            \n\n\n\n

            Part Nine: Emerging Issues and the Future Landscape<\/strong><\/h2>\n\n\n\n

            AI and Machine Learning in Patent Expiry Prediction<\/strong><\/h3>\n\n\n\n

            Several IP intelligence companies, including DrugPatentWatch, have begun applying machine learning models to patent expiry prediction. These models ingest public patent data, regulatory approval dates, litigation histories, and SPC\/PTE application records to generate probabilistic expiration dates that account for litigation risk, extension opportunities, and regulatory exclusivity interactions.<\/p>\n\n\n\n

            For a generic or biosimilar manufacturer, a model that predicts with 80 percent confidence that Drug X’s effective exclusivity ends in Q3 2027, rather than the nominal Q1 2028 date suggested by the base patent alone, can be the difference between being first-to-file on a generic application and being second.<\/p>\n\n\n\n

            For branded companies, similar models can flag vulnerabilities in their own patent estates that they may have missed: patents approaching expiration without filed PTE applications, SPCs that have not been filed in certain member states, or pediatric extension opportunities that have not been pursued.<\/p>\n\n\n\n

            The accuracy of these models depends on data quality. Patent extension calculations require precise regulatory dates, and those dates are sometimes inaccurate or incomplete in public databases. The companies that invest in data verification and curation get better model outputs.<\/p>\n\n\n\n

            The Unitary Patent and Future SPC Reform<\/strong><\/h3>\n\n\n\n

            As noted above, the Unitary Patent became operational in June 2023. As of mid-2025, uptake has been growing, with an increasing proportion of European patent grants being converted to Unitary Patents rather than validated nationally.<\/p>\n\n\n\n

            For SPC strategy, the critical question is whether a Unitary SPC will be available before the current generation of blockbuster drugs’ SPCs expire. If Unitary SPC legislation passes and is implemented in the late 2020s, companies that have been validating patents nationally in anticipation of national SPC applications will face a strategic choice: should they be filing Unitary Patents instead, positioning themselves to take advantage of a simpler Unitary SPC filing if that system becomes available?<\/p>\n\n\n\n

            The strategic answer depends on timing assumptions that no one can make with certainty. Companies are typically advised to maintain both options where possible: file patents as Unitary Patents where that makes sense, while also ensuring they can fall back on national SPC applications if Unitary SPCs are not available when needed.<\/p>\n\n\n\n

            GLP-1 Drugs and the Next Wave of Extension Battles<\/strong><\/h3>\n\n\n\n

            The extraordinary commercial success of GLP-1 receptor agonists, including semaglutide (Ozempic\/Wegovy, Novo Nordisk), tirzepatide (Mounjaro\/Zepbound, Eli Lilly), and their successors, makes their patent and extension status one of the most watched in pharmaceutical IP.<\/p>\n\n\n\n

            Semaglutide’s core composition patents in the U.S. begin expiring in the late 2020s. Novo Nordisk has multiple patents covering formulations, delivery devices, and specific uses, as well as SPC applications in multiple European jurisdictions. The extension strategy for semaglutide is being watched closely by biosimilar manufacturers around the world.<\/p>\n\n\n\n

            For tirzepatide, the composition patents similarly begin expiring in the early 2030s. The patent strategy, extension applications, and any Paragraph IV challenges filed against these drugs will shape the GLP-1 market for a decade.<\/p>\n\n\n\n

            Both drugs are eligible for pediatric extension in Europe if Pediatric Investigation Plans are completed and reflected in the label. The commercial value of six additional months of European exclusivity for drugs with this revenue profile is enormous.<\/p>\n\n\n\n

            The GLP-1 patent battles have not yet matured into the kind of extensive litigation that characterized Humira or Lipitor in their time, but they are coming. Observers who watch the Paragraph IV filings against semaglutide and tirzepatide patents will have early visibility into when generic and biosimilar manufacturers intend to challenge the exclusivity timelines.<\/p>\n\n\n\n

            Drug Pricing Policy and the Shadow It Casts<\/strong><\/h3>\n\n\n\n

            The Inflation Reduction Act (IRA) in the United States introduced Medicare drug price negotiation for certain high-expenditure drugs. The first drugs selected for negotiation included products whose patent protection was expiring within the relevant timeframe. The IRA created a specific provision allowing the Department of Health and Human Services to select small molecule drugs for negotiation nine years after their first FDA approval and biologics eleven years after approval, irrespective of patent status.<\/p>\n\n\n\n

            This creates a new dimension in the PTE calculation: for drugs subject to IRA negotiation, the financial benefit of extending patent protection may be partially offset by reduced revenues during the negotiation period. The interaction between IRA negotiation timelines and PTE extension periods requires companies to model their revenue outlook differently than before.<\/p>\n\n\n\n

            The IRA’s impact on the value of patent extensions is still being understood as the first negotiation cycles complete. There is academic debate about whether the IRA changes the incentive calculus for drug development, and specifically whether shortening the effective revenue period through negotiation affects the return on R&D investment in ways that ultimately affect drug availability.<\/p>\n\n\n\n

            \n\n\n\n

            Part Ten: Building the Internal Competency<\/strong><\/h2>\n\n\n\n

            The IP Department Structure for Extension Management<\/strong><\/h3>\n\n\n\n

            Companies that manage PTE and SPC applications well typically have a dedicated function within their IP department that tracks regulatory milestones. This function sits at the intersection of regulatory affairs, legal, and finance, because the inputs come from regulatory (the dates), the execution sits in legal (the applications), and the outputs flow to finance (the exclusivity models).<\/p>\n\n\n\n

            At large pharmaceutical companies, this might be a team of five to ten people globally, coordinating with local patent counsel in each jurisdiction where SPCs are filed. At mid-sized companies, it might be two or three people supported heavily by outside counsel networks.<\/p>\n\n\n\n

            The function requires specific skills: familiarity with patent prosecution, enough regulatory knowledge to understand what each FDA or EMA milestone means for the extension calculation, and project management capability to track dozens of concurrent deadlines across multiple jurisdictions.<\/p>\n\n\n\n

            Outside Counsel Coordination<\/strong><\/h3>\n\n\n\n

            For EU SPC filings, the coordination challenge is managing a network of patent attorneys in twenty-seven EU member states plus the UK, all receiving instructions from a central IP team and all operating under different national rules, languages, and fee schedules.<\/p>\n\n\n\n

            Large pharmaceutical companies typically retain two or three primary outside counsel firms with strong European networks that coordinate national filings on their behalf. These firms maintain relationships with local patent attorneys in each member state and handle the translation, filing, and fee payment logistics, reporting back to the company’s central IP team.<\/p>\n\n\n\n

            The company’s internal team focuses on strategy: which patents to use as basic patents, how to address the basic patent requirement for combination products, how to handle cases where the CJEU’s jurisprudence creates uncertainty. The outside firms focus on execution.<\/p>\n\n\n\n

            For U.S. PTE applications, the equivalent function is simpler: one USPTO filing coordinated with the FDA’s regulatory review period determination. Many companies use specialized patent prosecution counsel for PTE applications, particularly given the due diligence documentation requirements.<\/p>\n\n\n\n

            Technology Systems for Deadline Management<\/strong><\/h3>\n\n\n\n

            The IT infrastructure supporting patent extension management typically includes:<\/p>\n\n\n\n

            A patent management system (like CPA Global, Anaqua, or FoundationIP) that holds the patent portfolio data including expiration dates and annuity schedules.<\/p>\n\n\n\n

            A regulatory affairs system that holds the milestone dates for each drug’s development program, including IND dates, NDA filing dates, and approval dates across all jurisdictions.<\/p>\n\n\n\n

            A calendar and docketing system that translates regulatory milestones into IP filing deadlines, with automated alerts sent to responsible parties at six months, three months, one month, and two weeks before each deadline.<\/p>\n\n\n\n

            A document management system that holds the SPC and PTE applications, official communications from patent offices, and the underlying documentation supporting each application.<\/p>\n\n\n\n

            For many companies, these systems are not fully integrated, requiring manual reconciliation between regulatory and IP data. Building integration between regulatory milestone databases and IP docketing systems is a meaningful operational improvement that reduces the risk of missed deadlines due to information gaps.<\/p>\n\n\n\n

            \n\n\n\n

            Part Eleven: The Strategic Perspective<\/strong><\/h2>\n\n\n\n

            Thinking About Extensions as Part of Development Strategy<\/strong><\/h3>\n\n\n\n

            The most sophisticated pharmaceutical companies do not treat PTE and SPC applications as afterthoughts to the drug development process. They model the extension opportunity at the time of IND filing and use that model to inform development strategy decisions.<\/p>\n\n\n\n

            For example: if a company is choosing between two clinical development timelines (a more aggressive twelve-month NDA filing timeline after Phase III completion versus a more conservative eighteen-month timeline), the choice affects the PTE calculation. The more aggressive timeline produces a shorter regulatory review period and therefore a shorter PTE. If the drug’s commercial opportunity justifies the faster timeline for competitive reasons, the shorter extension is an acceptable cost. If the timelines are commercially equivalent, the longer regulatory review period may actually be preferable from an extension standpoint.<\/p>\n\n\n\n

            This may seem counterintuitive: companies generally want to maximize speed to market. But for a product in a therapeutic area without intense competitive pressure, deliberately optimizing the development timeline to maximize the extension period can be rational.<\/p>\n\n\n\n

            Similarly, the PIP completion timing affects the EU pediatric extension opportunity. If completing the pediatric studies before the initial marketing authorization application, rather than after, affects the SPC calculation, the timing decision is relevant to extension strategy.<\/p>\n\n\n\n

            The Interplay Between Orphan Drug Designation and Extensions<\/strong><\/h3>\n\n\n\n

            Orphan drug designations, available in both the U.S. and EU, provide market exclusivity periods that operate independently of patent protection: seven years in the U.S. and ten years in the EU. For drugs that receive orphan designation, the interaction between orphan exclusivity and patent extensions can produce complex stacking or replacement effects.<\/p>\n\n\n\n

            In the U.S., orphan drug exclusivity prevents the FDA from approving a competing same drug for the same indication for seven years, regardless of patent status. If a drug’s PTE extends its patent protection beyond the seven-year orphan exclusivity period, the patent remains the operative exclusivity mechanism. If the orphan exclusivity extends beyond the patent (including extension), the orphan exclusivity is the binding constraint.<\/p>\n\n\n\n

            In the EU, orphan exclusivity similarly interacts with SPC protection. Companies with orphan-designated drugs must model both timelines and ensure they are maximizing the longer of the two protection periods.<\/p>\n\n\n\n

            Willful Ignorance as a Compliance Risk<\/strong><\/h3>\n\n\n\n

            AstraZeneca’s antitrust problems over SPC representations illustrate a broader compliance principle: in the context of regulatory communications, representations to patent offices, and any statements about the dates underlying an SPC or PTE application, accuracy is not optional.<\/p>\n\n\n\n

            Companies have an affirmative obligation to represent regulatory dates accurately. If the ‘first authorization in the Community’ date is January 15, the SPC application must reflect January 15, not February 1 (the date it was published in an official journal) or March 15 (the date the product actually launched). The temptation to use a later date that produces a longer extension, whether through calculation error or deliberate misrepresentation, is the kind of conduct that regulators and courts treat seriously.<\/p>\n\n\n\n

            Internal compliance programs at pharmaceutical companies should include specific protocols for verifying the regulatory dates cited in SPC and PTE applications against primary source documents. Legal counsel signing off on these applications should be personally satisfied that the dates are correct, not simply accepting dates provided by regulatory affairs without verification.<\/p>\n\n\n\n

            \n\n\n\n

            Part Twelve: Country-Specific Nuances Worth Knowing<\/strong><\/h2>\n\n\n\n

            Switzerland: Non-EU, Non-EEA, Still Critical<\/strong><\/h3>\n\n\n\n

            Switzerland is not an EU member state and not part of the European Economic Area, yet it is home to several of the world’s largest pharmaceutical companies (Novartis, Roche, Lonza) and is a major prescription drug market. Switzerland has its own SPC system under the Patent Act, with rules that broadly parallel the EU system but are applied independently.<\/p>\n\n\n\n

            Swiss SPCs reference Swiss marketing authorizations granted by Swissmedic. Because Swissmedic operates independently of the EMA, the authorization dates for EU and Swiss purposes may differ substantially. Historically, Switzerland often granted marketing authorizations later than the EU for the same products, which could either extend or abbreviate the SPC duration compared to the EU, depending on the specific timing.<\/p>\n\n\n\n

            India, China, and Emerging Markets<\/strong><\/h3>\n\n\n\n

            India’s patent system, operating under the Patents Act 1970 as amended, does not provide pharmaceutical patent extensions of the kind available in the U.S. or EU. India’s Section 3(d), which prohibits the grant of patents for new forms of known substances that do not demonstrate significantly enhanced efficacy, has generated extensive litigation and significantly limited the ability of originator companies to obtain robust patent protection for incremental improvements to existing drugs.<\/p>\n\n\n\n

            China’s patent system has undergone significant reform in recent years, including the introduction of a pharmaceutical patent linkage system and a patent term compensation mechanism under amendments to the Chinese Patent Law effective in 2021. The compensation mechanism provides extensions for regulatory review delays, capped at five years with a maximum total patent life of fourteen years after drug approval, broadly analogous to the U.S. and EU systems.<\/p>\n\n\n\n

            China’s system is still maturing, and the implementing regulations and administrative practice continue to evolve. For companies with significant commercial interests in China, building Chinese regulatory date tracking into the global extension management system is increasingly important.<\/p>\n\n\n\n

            Brazil’s INPI has a specific process for pipeline patents (patents filed in Brazil that cover products already protected elsewhere), and the interaction between pipeline patents, Brazilian regulatory approval dates, and INPI’s examination timeline creates a complex landscape. Brazil’s ANVISA regulatory approval dates feed into pipeline patent term calculations in ways that require specialist Brazilian IP counsel.<\/p>\n\n\n\n

            South Korea and Taiwan<\/strong><\/h3>\n\n\n\n

            South Korea and Taiwan both have pharmaceutical patent extension systems that follow the general logic of the U.S. and EU models. South Korea’s Patent Act provides extensions for pharmaceutical products approved by the Ministry of Food and Drug Safety (MFDS). Taiwan’s patent system similarly compensates for regulatory review delays under the Intellectual Property Office.<\/p>\n\n\n\n

            Both markets are commercially significant for pharmaceutical companies, and both have active generic pharmaceutical industries that monitor patent expiration dates and extension applications closely. The competitive dynamics for products approaching patent expiry in South Korea and Taiwan often presage the dynamics that will follow in other markets.<\/p>\n\n\n\n

            \n\n\n\n

            The Practical Takeaway: What Separates Winners from Losers<\/strong><\/h2>\n\n\n\n

            The pharmaceutical companies that extract maximum value from their patent extension opportunities share several characteristics that distinguish them from those that leave extensions on the table.<\/p>\n\n\n\n

            They start tracking regulatory dates from the first IND filing, not from the date of NDA approval. By the time the FDA approves the drug, they have already computed the preliminary PTE, drafted the application, and identified the optimal patent to extend. The sixty-day window is used for final review, not drafting.<\/p>\n\n\n\n

            They maintain a global calendar that maps EU, UK, Japan, Canada, and Australia MA dates against SPC filing deadlines in each jurisdiction. No deadline surprises them because they track milestones months in advance.<\/p>\n\n\n\n

            They pursue pediatric extensions in the EU proactively. The PIP is agreed early in development, the pediatric studies are completed on schedule, and the label update to trigger the six-month extension is filed within the available window.<\/p>\n\n\n\n

            They select the patent to extend based on rigorous modeling, not default assumptions. The composition of matter patent is not automatically the right choice. The analysis covers all eligible patents, projects extension durations under different scenarios, and accounts for litigation vulnerability.<\/p>\n\n\n\n

            They know what competitors are doing. Using services like DrugPatentWatch and national SPC registers, they track competitor extension filings across all major markets. When a competitor’s SPC in Germany expires, they know months in advance that the generic entry window opens and their commercial team can respond.<\/p>\n\n\n\n

            They treat extension optimization as a business development function, not a legal formality. The IP team interacts with the commercial, regulatory, and finance teams to ensure that extension strategy feeds into product valuation, launch planning, and lifecycle management.<\/p>\n\n\n\n

            None of this is rocket science. It is disciplined tracking, coordinated execution, and strategic modeling applied to a set of legal mechanisms that are well understood. The companies that do it consistently win extensions that competitors miss. Over a portfolio of drugs across many years, those wins compound into billions of dollars of protected revenue.<\/p>\n\n\n\n

            \n\n\n\n

            Key Takeaways<\/strong><\/h2>\n\n\n\n
              \n
            • Patent Term Extensions (PTEs) in the U.S. and Supplementary Protection Certificates (SPCs) in the EU are the primary mechanisms for recovering patent term lost during mandatory regulatory review. Extensions of up to five years are available in both systems, with a six-month EU pediatric bonus available for compliant pediatric studies.<\/li>\n\n\n\n
            • The IND effective date (thirty days after submission in the U.S.) and the NDA\/BLA approval date are the foundational inputs to the U.S. PTE calculation. Errors or uncertainties in these dates translate directly into calculation errors.<\/li>\n\n\n\n
            • The sixty-day U.S. PTE filing window is absolute. Courts have never granted equitable relief for missed deadlines. Applications must be substantially drafted before FDA approval, not during the post-approval chaos of a drug launch.<\/li>\n\n\n\n
            • EU SPC applications must be filed within six months of the later of the basic patent grant or the marketing authorization in the Community. Twenty-seven separate national filings are required across EU member states, plus a separate UK filing post-Brexit.<\/li>\n\n\n\n
            • The CJEU’s ruling in Teva v. Gilead materially tightened the requirements for combination product SPCs. Patents claiming individual compounds that are later combined into approved combination products may not qualify as the basic patent unless the combination was specifically identifiable in the patent as filed.<\/li>\n\n\n\n
            • Japan’s PTE system uniquely allows multiple patents covering the same product to each receive separate extensions. The three-month filing window is the shortest of any major jurisdiction.<\/li>\n\n\n\n
            • Pediatric extensions in the EU represent six months of additional SPC coverage. For drugs generating over $1 billion annually in European revenues, this bonus is worth hundreds of millions of dollars.<\/li>\n\n\n\n
            • Applicant delays during the U.S. regulatory review period reduce the PTE. Companies that document their regulatory interactions contemporaneously are better positioned to minimize attributed delays.<\/li>\n\n\n\n
            • The IRA’s Medicare drug price negotiation mechanism creates a new variable in PTE strategy for U.S. drugs. The interaction between negotiation timelines and extension periods requires modeling that was not necessary before 2022.<\/li>\n\n\n\n
            • Tools like DrugPatentWatch aggregate patent expiration, SPC status, and Paragraph IV filing data across thousands of drugs, enabling competitive intelligence that feeds directly into generic entry timing models and branded company lifecycle management.<\/li>\n<\/ul>\n\n\n\n
              \n\n\n\n

              FAQ<\/strong><\/h2>\n\n\n\n

              Q1: Can a pharmaceutical company file a PTE application for a patent that is not listed in the FDA Orange Book?<\/strong><\/p>\n\n\n\n

              Yes. U.S. PTE eligibility under 35 U.S.C. \u00a7 156 does not require that the patent be listed in the FDA Orange Book. The Orange Book listing requirement applies to the Hatch-Waxman patent certification system, which is a separate mechanism for linking patent status to ANDA approvals. A patent covering a drug product, manufacturing process, or method of use is eligible for PTE if it meets the statutory criteria, regardless of Orange Book listing status. In practice, most PTEs are filed for patents that are also Orange Book-listed, because those are typically the commercially significant patents, but the eligibility is not contingent on listing.<\/p>\n\n\n\n

              Q2: What happens to an EU SPC when the underlying basic patent is found invalid in post-grant opposition proceedings?<\/strong><\/p>\n\n\n\n

              If the European Patent Office (EPO) revokes a European patent through opposition proceedings, any SPCs based on that patent in EU member states lose their legal basis. The national effects of EPO revocation apply retroactively under EPC Article 68: the patent is deemed never to have had its initial effects from the date of revocation. SPCs granted on the basis of the revoked patent are similarly voided. Generic manufacturers who successfully oppose a European patent in EPO proceedings therefore also eliminate the associated SPCs across all validated countries simultaneously, which is one reason EPO oppositions are frequently used as a strategic tool by generic manufacturers even when the opposition period (nine months from grant) is tight.<\/p>\n\n\n\n

              Q3: How does a company determine whether a drug’s Pediatric Investigation Plan has been fully complied with for the EU six-month SPC extension?<\/strong><\/p>\n\n\n\n

              The EMA’s Pediatric Committee (PDCO) issues a compliance check decision under Article 23 of the Pediatric Regulation (EC) No. 1901\/2006 confirming that the agreed PIP has been completed. The marketing authorization holder must apply for this compliance check and receive a positive decision from the PDCO before the national patent offices will grant the six-month Paediatric Extension. The compliance check requires that the results of the pediatric studies are reflected in the Summary of Product Characteristics (SmPC), meaning the label must actually contain the pediatric data. A company that completes pediatric studies but fails to update the label, or fails to obtain the PDCO compliance decision within the applicable window, cannot obtain the extension.<\/p>\n\n\n\n

              Q4: What strategic considerations apply when a drug has multiple patented inventions, some eligible for SPC in the EU and some not, and the company must choose which to use as the basic patent for SPC filings?<\/strong><\/p>\n\n\n\n

              The selection of the basic patent for an EU SPC involves modeling several competing considerations. The basic patent must satisfy the ‘protection’ requirement of the SPC Regulation, as interpreted by the CJEU’s jurisprudence, so validity of the SPC grant is the first filter. Beyond that, the company should compare the expiration dates of each candidate patent: an SPC’s duration is calculated as the gap between the patent filing date and the marketing authorization date, minus five years. Patents filed later therefore produce shorter SPCs for the same marketing authorization date. Companies should model the SPC duration from each candidate patent and identify which produces the longest protection. For combination products, the analysis must also account for the risk that a broad claim patent may not qualify under Teva v. Gilead standards, making a narrower but clearly qualifying patent the safer choice even if it produces a somewhat shorter SPC.<\/p>\n\n\n\n

              Q5: How do companies handle PTE applications when the drug has received approval for multiple indications at different times, with different NDA approval dates for each indication?<\/strong><\/p>\n\n\n\n

              Under U.S. law, only the first FDA approval of the product triggers PTE eligibility. If a drug receives NDA approval for Indication A in 2018 and then a supplemental NDA approval for Indication B in 2021, the 2018 date governs the PTE calculation for any patents covering the drug product itself. However, if Indication B is covered by a different method of use patent that was not eligible for extension based on the 2018 approval (because it was not claiming anything that received approval in 2018), that method of use patent might separately qualify for a PTE based on the 2021 approval of Indication B, provided it otherwise meets all eligibility criteria and has not already been extended. This scenario requires careful patent-by-patent analysis: the question is whether each patent ‘required’ the regulatory review period that is being claimed as the basis for extension. Companies developing drugs for multiple indications should track each NDA filing and approval separately and analyze extension eligibility across their entire patent portfolio in light of each approval event.<\/p>\n\n\n\n

              \n\n\n\n

              References<\/strong><\/h2>\n\n\n\n

              [1] IQVIA Institute for Human Data Science. (2024). The Global Use of Medicines 2024: Outlook to 2028<\/em>. IQVIA.<\/p>\n\n\n\n

              [2] Grabowski, H., Long, G., Mortimer, R., & Boyo, A. (2016). Updated trends in US brand-name and generic drug competition. Journal of Medical Economics<\/em>, 19(9), 836\u2013844. https:\/\/doi.org\/10.1080\/13696998.2016.1176578<\/p>\n\n\n\n

              [3] DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics<\/em>, 47, 20\u201333. https:\/\/doi.org\/10.1016\/j.jhealeco.2016.01.012<\/p>\n\n\n\n

              [4] Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (codified as amended at 35 U.S.C. \u00a7 156).<\/p>\n\n\n\n

              [5] Court of Justice of the European Union. (2018, July 25). Teva UK Ltd and Others v. Gilead Sciences Inc.<\/em> (Case C-121\/17). ECLI:EU:C:2018:585.<\/p>\n\n\n\n

              [6] IQVIA Institute for Human Data Science. (2023). Medicine use and spending in the U.S.: A review of 2022 and outlook to 2027<\/em>. IQVIA.<\/p>\n\n\n\n

              [7] Court of Justice of the European Union. (2018, July 25). Teva UK Ltd and Others v. Gilead Sciences Inc.<\/em> (Case C-121\/17). ECLI:EU:C:2018:585.<\/p>\n\n\n\n

              [8] European Commission. (2005, June 15). Commission Decision of 15 June 2005 relating to a proceeding under Article 82 of the EC Treaty and Article 54 of the EEA Agreement (Case COMP\/A.37.507\/F3 – AstraZeneca)<\/em>. Official Journal of the European Union, L 332, 24\u2013124.<\/p>\n\n\n\n

              [9] Court of Justice of the European Union. (2012, November 19). Neurim Pharmaceuticals (1991) Ltd v. Comptroller-General of Patents<\/em> (Case C-130\/11). ECLI:EU:C:2012:713.<\/p>\n\n\n\n

              [10] Initiative for Medicines, Access & Knowledge (I-MAK). (2021). Overpatented, Overpriced: How Excessive Pharmaceutical Patenting Is Extending Monopolies and Driving Up Drug Prices<\/em>. I-MAK.<\/p>\n","protected":false},"excerpt":{"rendered":"

              The difference between a blockbuster drug that earns another five years of protected revenue and one that faces generic competition […]<\/p>\n","protected":false},"author":1,"featured_media":38561,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38553","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38553"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38553\/revisions"}],"predecessor-version":[{"id":38562,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38553\/revisions\/38562"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38561"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}